- Home
- GT vs VERA Comparison
GT vs VERA Comparison
Compare GT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GT
- VERA
- Stock Information
- Founded
- GT 1898
- VERA 2016
- Country
- GT United States
- VERA United States
- Employees
- GT N/A
- VERA N/A
- Industry
- GT Automotive Aftermarket
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- GT Consumer Discretionary
- VERA Health Care
- Exchange
- GT Nasdaq
- VERA Nasdaq
- Market Cap
- GT 2.4B
- VERA 2.8B
- IPO Year
- GT N/A
- VERA 2021
- Fundamental
- Price
- GT $8.62
- VERA $42.60
- Analyst Decision
- GT Buy
- VERA Strong Buy
- Analyst Count
- GT 3
- VERA 9
- Target Price
- GT $13.30
- VERA $59.22
- AVG Volume (30 Days)
- GT 4.9M
- VERA 548.9K
- Earning Date
- GT 02-10-2025
- VERA 11-07-2024
- Dividend Yield
- GT N/A
- VERA N/A
- EPS Growth
- GT N/A
- VERA N/A
- EPS
- GT N/A
- VERA N/A
- Revenue
- GT $19,047,000,000.00
- VERA N/A
- Revenue This Year
- GT N/A
- VERA N/A
- Revenue Next Year
- GT N/A
- VERA N/A
- P/E Ratio
- GT N/A
- VERA N/A
- Revenue Growth
- GT N/A
- VERA N/A
- 52 Week Low
- GT $7.27
- VERA $14.20
- 52 Week High
- GT $14.97
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- GT 33.77
- VERA 37.73
- Support Level
- GT $10.02
- VERA $40.74
- Resistance Level
- GT $10.26
- VERA $49.77
- Average True Range (ATR)
- GT 0.41
- VERA 2.22
- MACD
- GT -0.25
- VERA -0.78
- Stochastic Oscillator
- GT 7.84
- VERA 18.87
About GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.